Back to News
Market Impact: 0.2
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
Source: zacks.com
Healthcare & Biotech
Puma Biotechnology has initiated the Phase II ALISCA-Lung2 trial of alisertib combined with paclitaxel for patients with advanced small-cell lung cancer. The study advances the company’s oncology pipeline, but no efficacy, safety, enrollment, or commercial data were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
PBYI0.55
More News
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- Karyopharm stock rating cut to neutral by Rodman on bankruptcy
- RA Capital Management sells $9.13M in Lenz Therapeutics shares
- Bright Minds shares fall as BTIG cuts price target on clinical hold
- Vertex Pharma meets Q3 estimates, raises revenue guidance
- Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future